Taltz (ixekizumab) / Eli Lilly - LARVOL DELTA

Prevalence and clinical relevance of anti-drug antibodies in psoriatic arthritis: a systematic review. (PubMed, RMD Open) - "ADA prevalence in PsA varies widely between bDMARDs and across studies of the same bDMARD. ADAs appear most clinically relevant for TNF inhibitors, whereas evidence for other biological classes remains limited. Immunoassay heterogeneity limits comparability, highlighting the need for standardised prospective studies."

Journal • Review • Immunology • Inflammatory Arthritis • Oncology • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies • IL12A • IL23A

Differential Risk of Paradoxical Alopecia between Secukinumab and Ixekizumab: A Comparative Pharmacovigilance Analysis Using EudraVigilance and FAERS Database (EADV 2026) - No abstract available

Adverse events • Alopecia • Immunology

Comparative Pancreatitis Safety Signal of IL-17 Versus IL-23 Inhibitors: A FAERS Pharmacovigilance Study (ACG 2026) - "Reports containing the preferred term âpancreatitisâ were identified for IL-17 inhibitors (secukinumab, ixekizumab, bimekizumab) and IL-23 inhibitors (guselkizumab, risankizumab, tildrakizumab). 707 cases of pancreatitis were reported. Among IL-17 inhibitors, 385 reports were associated with secukinumab, 43 with ixekizumab, and 19 with bimekizumab. Secukinumab demonstrated a significant disproportionality signal [ROR 1.379 (95% CI 1.248â1.525); PRR 1.378; ϲ 39.8; p< 0.05]."

Adverse events • Clinical • Immunology • Inflammation • Inflammatory Arthritis • Pancreatitis • Psoriasis • Psoriatic Arthritis • Seronegative Spondyloarthropathies • IL17A • IL23A • ROR1

Histological findings in new onset colitis associated with IL-17a inhibitor therapy (ECP 2026) - " In total, IL-17a inhibitor-associated colitis was the favoured diagnosis for 16 patients, 9 men and 7 women aged 24-75 years (mean 49.4) who received IL-17a inhibitors (secukinumab 10/16, ixekizumab 5/16, bimekizumab 1/16) for various indications, most commonly psoriatic arthritis (8/16). The morphological range of IL-17a inhibitor therapy-associated colitis is wide and may be hard to distinguish from IBD, particularly when drug history is unknown. In patients with de novo gastrointestinal inflammation after introduction of IL-17a inhibitor treatment, cessation of the drug may lead to full histological remission."

Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Arthritis • Inflammatory Bowel Disease • Psoriatic Arthritis • Seronegative Spondyloarthropathies • Ulcerative Colitis • IL17A

Practical Saudi Guidelines on management of moderate-to-severe psoriasis: 2026 update. (PubMed, J Dermatolog Treat) - "For pediatric patients, the guidelines recommend early initiation of biologic therapy, with etanercept, secukinumab, ixekizumab, and adalimumab as preferred options. These Saudi national guidelines offer a comprehensive, evidence-based framework for managing moderate-to-severe psoriasis in adults and pediatric patients."

Clinical guideline • Journal • Review • Dermatology • Immunology • Oncology • Pediatrics • Psoriasis • IL12A • IL23A

Biologic and targeted synthetic therapies in ankylosing spondylitis: a pharmacological review. (PubMed, Front Pharmacol) - "TNF inhibitors (adalimumab, infliximab, etanercept, golimumab, certolizumab pegol) typically achieve Assessment of Spondyloarthritis International Society 40% improvement (ASAS40) rates of 40%-58% at 12-24 weeks versus 13%-24% with placebo, and maintain clinical benefit in many patients over 5-8 years. IL-17 inhibitors (secukinumab, ixekizumab, bimekizumab, brodalumab, netakimab) yield broadly similar ASAS40 responses (30%-50% versus 10%-20% placebo) and are particularly useful in patients with concomitant psoriasis with substantially reduced risk of tuberculosis reactivation. JAK inhibitors (tofacitinib, upadacitinib) represent the newest class, offering oral administration with ASAS40 responses of 40%-52% versus 13%-26% for placebo in both biologic-naïve and biologic-experienced AS, though cardiovascular safety considerations necessitate careful patient selection. Therapeutic selection should consider comorbidities (uveitis favors TNF monoclonal antibodies;..."

Journal • Review • Ankylosing Spondylitis • Back Pain • Cardiovascular • Dermatology • Gastroenterology • Gastrointestinal Disorder • Immunology • Infectious Disease • Inflammatory Arthritis • Inflammatory Bowel Disease • Musculoskeletal Pain • Ocular Inflammation • Oncology • Ophthalmology • Pain • Psoriasis • Pulmonary Disease • Respiratory Diseases • Rheumatology • Seronegative Spondyloarthropathies • Spondylarthritis • Tuberculosis • Uveitis • IL17A

Effectiveness of brodalumab in biologic-experienced adults with moderate to severe plaque psoriasis: a focused narrative review. (PubMed, J Dermatolog Treat) - "In real-world studies of patients with treatment failure on anti-IL-17 agents (secukinumab and/or ixekizumab), brodalumab achieved PASI 75, PASI 90, and PASI 100 in 47.8%-81.7%, 40.0%-58.9%, and 28.0%-50.0% of patients, respectively, after 12-16 weeks of treatment. Studies with longer-term follow-up have suggested that responses to brodalumab are durable in biologic-experienced patients. Literature evaluated in this narrative review positions brodalumab as a rational, safe, and effective treatment option for adults with moderate to severe plaque psoriasis who have an inadequate response/loss of an initial response to their existing biologic agent."

Journal • Review • Dermatology • Immunology • Oncology • Psoriasis • IL12A • IL23A • TNFA

Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty (clinicaltrials.gov) - P2 | N=80 | Recruiting | Sponsor: NYU Langone Health | Not yet recruiting ➔ Recruiting | Trial completion date: Sep 2027 ➔ Jan 2028 | Initiation date: Sep 2025 ➔ Dec 2025 | Trial primary completion date: Sep 2027 ➔ Jan 2028

Enrollment open • Trial completion date • Trial initiation date • Trial primary completion date • Orthopedics • Psoriatic Arthritis • Rheumatology

Short-term efficacy of biologics targeting the IL-17/IL-23 axis in scalp, nail, and palmoplantar psoriasis: a network meta-analysis of randomized controlled trials. (PubMed, Front Immunol) - "For palmoplantar psoriasis, secukinumab ranked highest (SUCRA = 79.7%), followed by bimekizumab (72.2%) and ustekinumab (69.7%)...For scalp psoriasis, brodalumab (87.7%) and ixekizumab (86.9%) ranked highest, followed by bimekizumab (69.0%) and guselkumab (65.1%); the brodalumab estimate relied on a single contributing study...Bimekizumab and ixekizumab showed consistently favorable rankings across sites, but treatment selection should consider certainty of evidence, sensitivity analyses, long-term response, and patient-level factors. https://www.crd.york.ac.uk/PROSPERO, identifier CRD420251271255."

Clinical • Journal • Retrospective data • Review • Dermatology • Immunology • Psoriasis • IL17A • IL23A

Anti-IL-17 therapy in people living with HIV who have cutaneous psoriasis: A four-patient case series. (PubMed, Int J STD AIDS) - "Psoriasis Area Severity Index (PASI) scores, CD4 cell counts, HIV RNA levels, treatment duration and adverse events were obtained from medical records.ResultsThree patients received secukinumab and one received ixekizumab. No adverse events were observed during follow-up.ConclusionAnti-IL-17 therapy was associated with clinical improvement without observed deterioration in immunological or virological parameters in this small case series. Larger prospective studies are required before conclusions regarding safety can be drawn."

Journal • Dermatology • Human Immunodeficiency Virus • Immunology • Infectious Disease • Psoriasis • CD4 • IL17A

Dose Reduction of IL17 and IL23 Inhibitors in Psoriasis (BeNeBio study): An International, Pragmatic, Multicentre, Randomised, Controlled, Non-Inferiority Trial. (PubMed, Lancet Reg Health Eur) - P4 | "Patients with stable low disease activity on registered dosages of IL17i (secukinumab, ixekizumab, bimekizumab, brodalumab) or IL23i (guselkumab, risankizumab, tildrakizumab) were eligible. Disease-activity guided, stepwise interval prolongation of IL17i and IL23i in patients with controlled psoriasis is an effective and safe strategy to reduce unnecessary exposure to these expensive drugs. ZonMw (the Netherlands Organization for Health Research and Development), KCE Trials (the Belgian Health Care Knowledge Centre)."

Head-to-Head • Journal • Dermatology • Immunology • Psoriasis • IL17A

IL-17 ligand-targeting inhibitors in psoriatic arthritis: a focused systematic review and network meta-analysis of efficacy, safety, and certainty of evidence. (PubMed, Front Immunol) - "Ixekizumab Q2W had the highest ACR50 P-score, followed by bimekizumab 160 mg with loading and ixekizumab Q4W; however, active-treatment confidence intervals overlapped...Sonelokimab and izokibep showed favorable exploratory estimates but very low certainty...The protocol was registered in PROSPERO (CRD420251156756). https://www.crd.york.ac.uk/PROSPERO/view/CRD420251156756, identifier CRD420251156756."

Clinical • Journal • Retrospective data • Review • Immunology • Infectious Disease • Inflammatory Arthritis • Psoriasis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies • IL17A

Risk of Incident Inflammatory Bowel Disease Among Patients With Psoriasis Treated With IL-17 Versus TNF Inhibitors: A Propensity-Matched TriNetX Study (ACG 2026) - "Adults (â¥18 years) with psoriasis initiating an IL-17 inhibitor (secukinumab, ixekizumab, brodalumab, or bimekizumab) were compared with those starting a TNF inhibitor (adalimumab, infliximab, golimumab, or certolizumab pegol) after diagnosis...Cohorts underwent 1:1 propensity score matching on age, sex, race, ethnicity, diabetes, obesity, celiac disease, tobacco use, psoriatic arthritis (a disease-severity marker), and NSAID, antimicrobial, glucocorticoid, and methotrexate use, yielding 20,547 patients per cohort... After excluding prior IBD, 20,368 IL-17 and 18,987 TNF inhibitor users remained. At 1 year, incident IBD occurred in 46 IL-17 versus 79 TNF users (0.2% vs 0.4%), with significantly lower risk for IL-17 (relative risk [RR] 0.54, 95% CI 0.38â0.78; hazard ratio [HR] 0.56, 95% CI 0.39â0.81; log-rank p=0.002). At 3 years, IBD occurred in 85 versus 161 patients (0.4% vs 0.8%; RR 0.49, 95% CI 0.38â0.64; HR 0.54, 95% CI 0.42â0.70;..."

Clinical • Celiac Disease • Crohn's disease • Dermatology • Diabetes • Gastroenterology • Gastrointestinal Disorder • Genetic Disorders • Immunology • Inflammation • Inflammatory Arthritis • Inflammatory Bowel Disease • Metabolic Disorders • Nicotine Addiction • Obesity • Psoriasis • Psoriatic Arthritis • Seronegative Spondyloarthropathies • Ulcerative Colitis • IL17A

Factors Associated With PASI90 Maintenance Without Flare-Up and Predictors of Biologics Discontinuation in Psoriasis: Two-Center Retrospective Cohort Study in Korea. (PubMed, Ann Dermatol) - "Secukinumab, lower BMI, and biologic-naïve status favored durable PASI90 without flare-up. Obesity, family history, and adalimumab predicted drug discontinuation. Early treatment response strongly predicted long-term efficacy."

Journal • Retrospective data • Dermatology • Genetic Disorders • Immunology • Obesity • Psoriasis

Rethinking Biologic Failure: Ixekizumab Rescues Secukinumab Secondary Failure Through Intra-Class IL-17A Inhibitors Switching (EADV 2026) - No abstract available

Dermatology • Dermatopathology • Immunology • Psoriasis • IL17A

Risks of breast or prostate cancer recurrence and a second cancer in patients with inflammatory arthritis following treatment with biologic and targeted synthetic DMARDs - A nationwide cohort study (EULAR 2026) - "Eligible drugs included all five TNFi, non-TNFi bDMARDs (abatacept, rituximab, sarilumab, tocilizumab (for RA), sekukinumab, ixekizumab, bimekizumab (for SpA/PsA), and tsDMARDs, that is JAK inhibitors (baricitinib, filgotinib, tofacitinib, upadacitinib). The corresponding analyses of non-TNFi-bDMARDs, and in particular tsDMARDs, were limited by few events. The findings are clinically reassuring, supporting the safety of TNFi when treating IA in patients with a prior breast or prostate cancer."

Clinical • Ankylosing Spondylitis • Breast Cancer • Genito-urinary Cancer • Immunology • Inflammatory Arthritis • Oncology • Prostate Cancer • Psoriatic Arthritis • Rheumatoid Arthritis • Rheumatology • Seronegative Spondyloarthropathies • Solid Tumor • Spondylarthritis

FTB-918: A Dual Targeting Antibody With TRBV9+ T Cell Depletion and IL-17A Neutralization for the Treatment of Axial Spondyloarthritis (ACR Convergence 2026) - "FTB-918 was also able to neutralize IL17 both in vitro (Figure 2A), and in vivo (Figure 2B) as effectively as an approved IL17 inhibitor, ixekizumab. We have developed a high-affinity antibody, FTB-918, capable of depleting TRBV9+ T cells and neutralizing IL17A... We have developed a high-affinity antibody, FTB-918, capable of depleting TRBV9+ T cells and neutralizing IL17A. FTB-918 has robust functionality addressing two distinct mechanisms of axSpA immunopathogenesis and disease progression. The pre-clinical data illustrate the potential for FTB-918 to offer differentiated results from existing axSpA therapeutics, addressing the ongoing unmet need in this indication."

Ankylosing Spondylitis • Immunology • Inflammatory Arthritis • Seronegative Spondyloarthropathies • Spondylarthritis • CD8 • IL17A

Ixekizumab Plus Tirzepatide Demonstrated Greater Disease Control at 52 Weeks Versus Ixekizumab Alone With Incremental Improvement From Week 36 in Adults With Psoriatic Arthritis and Overweight or Obesity: Results From a Randomised Clinical Trial (ACR Convergence 2026) - P3 | "IXE+TZP showed benefit in disease activity as early as W4 and achieved the primary endpoint with clinically meaningful improvements at W364. At W52, it demonstrated greater ACR50 response and broader improvements in disease activity, weight and metabolic control than IXE alone, with no new safety concerns, supporting integrated care for these patients."

Clinical • Cardiovascular • Genetic Disorders • Immunology • Inflammatory Arthritis • Obesity • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies

Real-World Patient Experiences with Concomitant Ixekizumab and Tirzepatide in Psoriatic Arthritis: Patients Recruited from the Zepbound® Savings for Taltz® US Customer Support Program (ACR Convergence 2026) - No abstract available

Clinical • Real-world • Real-world evidence • Immunology • Inflammatory Arthritis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies

Clinical and Economic Outcomes of Psoriatic Arthritis Patients with Overweight or Obesity Treated with Ixekizumab and with Tirzepatide: a Modeling Study (ACR Convergence 2026) - No abstract available

Clinical • HEOR • Genetic Disorders • Immunology • Inflammatory Arthritis • Obesity • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies

Ixekizumab With Tirzepatide Was Associated With Reduced CV Risk Factors and Calculated CV Risk Beyond Ixekizumab Alone in Psoriatic Disease and Obesity (ACR Convergence 2026) - No abstract available

Clinical • Genetic Disorders • Immunology • Obesity

Ixekizumab and Concomitant Tirzepatide Achieved Early Disease Control in Adults with Psoriatic Arthritis and Obesity/Overweight: Phase 3b TOGETHER-PsA Trial (ACR Convergence 2026) - No abstract available

Clinical • P3 data • Genetic Disorders • Immunology • Inflammatory Arthritis • Obesity • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies

Ixekizumab With Tirzepatide in Psoriasis or Psoriatic Arthritis: A Pooled Analysis of Phase 3b Randomized Controlled Trials (ACR Convergence 2026) - No abstract available

P3 data • Retrospective data • Dermatology • Immunology • Inflammatory Arthritis • Psoriasis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies

A Phase 4, Prospective, Open-Label Study to Assess the Effectiveness of Adding Tirzepatide After Initiation of Ixekizumab in Adults With Psoriatic Arthritis and Overweight or Obesity (ACR Convergence 2026) - No abstract available

Clinical • P4 data • Genetic Disorders • Immunology • Inflammatory Arthritis • Obesity • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies

Biochemical, radiological and histological effects of ixekizumab on skin tissue in a bleomycin-induced systemic sclerosis mouse model. (PubMed, Clin Exp Rheumatol) - "IXE, an IL-17A inhibitor, reduced tissue fibrosis-related changes in a BLM-induced SSc model. This biological agent is thought to suppress mechanisms involved in SSc pathogenesis and showed similar antifibrotic trends to MMF, with no statistically significant differences observed between the two treatment groups for histopathological scores."

Journal • Preclinical • Fibrosis • Immunology • Inflammation • Scleroderma • Systemic Sclerosis • TGFB1 • TNFA